X

Trial Profile

PRASFIT-ACS Study: PRASugrel Compared to Clopidogrel For Japanese PatIenTs with ACS Undergoing PCI

Status: Completed

Phase of Trial: Phase III

Latest Information Update: 07 May 2018

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Prasugrel (Primary) ; Aspirin; Clopidogrel
Indications Acute coronary syndromes; Embolism and thrombosis
Focus Registrational; Therapeutic Use
Acronyms PRASFIT-ACS
Sponsors Daiichi Sankyo Company; Ube Industries

Most Recent Events

12 Mar 2018 Results assessing safety and efficacy presented at the 67th Annual Scientific Session of the American College of Cardiology
20 May 2016 New source identified and integrated (Japan Pharmaceutical Information Center - Clinical Trials Information; JapicCTI101339)
22 Apr 2014 Primary endpoint 'Major-adverse-cardiac-event-rate' has been met.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com